Navigation Links
Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
Date:12/3/2008

CHICAGO, Dec. 3 /PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI) has equivalent sensitivity and better specificity than breast MRI in patients with inconclusive findings after mammography and ultrasound in the diagnosis of breast cancer, according to findings presented today at the annual meeting of the Radiological Society of North America (RSNA). BSGI is a molecular breast imaging technique used as an adjunctive tool to mammography that can identify lesions independent of tissue density.

"The purpose of this study was to compare MRI and BSGI in women with indeterminate findings after applying mammography and ultrasound. We found BSGI has virtually equal sensitivity and better specificity than breast MRI in the diagnosis of breast cancer," said Dr. Leora Lanzkowsky.

Dr. Leora Lanzkowsky, as Medical Director of the Eisenhower Medical Center in Rancho Mirage, CA and her colleagues conducted BSGI and breast MRI on patients with complex, inconclusive mammographic and/or ultrasonic findings. In their group of 48 patients with 63 abnormalities, BSGI and MRI yielded consistent results in 37 of these areas and were inconsistent in 26. MRI was inconclusive in a greater number of benign cases -- 10 versus three on BSGI. Overall, in this group of patients with difficult to diagnose breast findings, the sensitivity of BSGI and MRI was 96 percent and 88 percent respectively; specificity was 46 percent and 27 percent respectively.

The advantages of BSGI over MRI include ease of interpretation with fewer images generated, and better tolerance of the test by patients. In addition, BSGI can be used in all patients including those with ferromagnetic implants or renal insufficiency.

BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the BSGI image.

"Both tests are good in detecting breast cancer with similar sensitivity for cancer. Along with benefits of cost-effectiveness and comfort, BSGI can be more helpful in excluding inconclusive MRI results. The use of BSGI in this group can result in fewer unnecessary MRI guided biopsies. The reassurance from a truly negative test, indicating that she does not have breast cancer, is priceless information for the patient," said Dr. Lanzkowsky. The work will continue at the Nevada Imaging Centers in Las Vegas, where a new state of the art breast center in association with a high risk clinic will incorporate the Breast specific gamma imaging technology with other state of the art technologies in the assessment of women with both moderate as well as high risk for the development of breast cancer.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
(Date:2/17/2017)... ... 17, 2017 , ... Program will serve more than 5,000 ... U.S. Soccer Foundation announced today that they have awarded nine grants to expand ... Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving to ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer ... Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part of ... anatomic and molecular pathology workflow solution, as well as its new precision medicine ...
(Date:2/17/2017)... ... ... Top neuroendocrine cancer doctors, nurses and specialists from around the world will ... in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive director of ... hosting over 60 faculty members and addressing unmet needs of the NET community. ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
Breaking Medicine Technology: